Verrucarin A (Muconomycin A) is a Type D macrocyclic mycotoxin. Verrucarin A (VA), derived from the pathogen fungus Myrothecium verrucaria, is a protein synthesis inhibitor that inhibits the growth of leukemia cell lines and activates caspases, apoptosis, and inflammatory signaling in macrophages. It effectively increases the phosphorylation of p38 MAPK and diminishes the phosphorylation of ERK/Akt. Additionally, Verrucarin A causes cell cycle deregulation through the induction of p21 and p53 [1] [2].

Verrucarin A, at concentrations ranging from 0 to 0.6 μM/ml over 24 to 48 hours, exhibits a time- and dose-dependent inhibition of growth in the MCF-7 human breast cancer cell line. It effectively raises the levels of reactive oxygen species (ROS), which leads to a reduction in mitochondrial membrane potential (Δψm). This reduction triggers an increase in the Bax/Bcl-2 ratio, ensuing the release of cytochrome c, activation of caspases, PARP degradation, and ultimately inducing apoptosis. The cell viability assay further substantiates these findings, demonstrating significant growth inhibition of MCF-7 cells in a dose- and time-responsive manner, with IC50 values of 0.41 and 0.29 μM/ml for 24- and 48-hour treatment periods, respectively.